Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Inclusion Criteria: * § Age \> or equal to 18 years.§ * Performance status inferior or equal to 1 (WHO criteria) * Histologically proven breast cancer, non metastatic, with clinical tumor diameter \> or equal to 2 cm. * HR negative and HER 2 negative. * Clinical stage II and IIIa. * Non prior treated patients either by surgery, radiotherapy, hormonotherapy or chemotherapy.§ * Adequate hematological, renal and hepatic functions : neutrophils \> 2.109 /L, platelets \> 100.109 /L, Hb \> 10 g/dL, normal bilirubin, ASAT and ALAT inferior or equal to 2,5 ULN (upper normal limit), alkaline phosphatases £ 2,5 ULN, creatinine \< 140 µmol/L or creatinine clearance \> 60 mL/min.§ * Written informed consent§ * Affiliation with social security system (or profit being of such a mode) according to terms' of the law of August 9, 2004. Exclusion Criteria: * Male patient. * Pregnant or lactating women or childbearing potential with no efficacy contraception. * Other breast cancer form and particularly inflammatory form and/or negliged (T4b or T4d).§ * Non measurable tumor. * Prior surgery or primary axillary dissection. * Prior treatment for this new breast cancer. * Under guardianship patient * Patient with antecedent of second cancer, excepted in situ uterine carcinoma or baso-cellular cutaneous cancer considered as definitively cured. * Patient with an associated pathology considered incompatible with the study.§ Cardiac, renal, medullar, respiratory or hepatic insufficiency. * Significant neurological or psychiatric troubles.§ Symptomatic or evolutive troubles in CNS or metastasis. * Peripheral neuropathy \> grade 2 NCI-CTC (version 3.0) * Previous allergy with polysorbate 80. * Concomitant treatment with a drug tested in a clinical trial, participation to another clinical study, for the last thirty days or prior chemotherapy. * Patients non stable for the following 6 months or leaving at a great distance of the participating center.